Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Essential surgery as a key component of primary health care: reflections on the 40th anniversary of Alma-Ata.

Griswold DP, Makoka MH, Gunn SWA, Johnson WD.

BMJ Glob Health. 2018 Sep 6;3(Suppl 3):e000705. doi: 10.1136/bmjgh-2017-000705. eCollection 2018. No abstract available.

2.

Traumatic brain injury: a global challenge.

Johnson WD, Griswold DP.

Lancet Neurol. 2017 Dec;16(12):949-950. doi: 10.1016/S1474-4422(17)30362-9. Epub 2017 Nov 6. No abstract available.

PMID:
29122521
3.

Minors' rights to refuse medical treatment requested by their parents: remaining issues.

Griswold DP, Griswold DB.

J Am Acad Nurse Pract. 2000 Aug;12(8):325-8.

PMID:
11930454
4.

Excision assay for initial evaluation of antitumor drug activity in mice bearing human tumor xenografts.

Dykes DJ, Harrison SD Jr, Mayo JG, Griswold DP Jr.

J Natl Cancer Inst. 1992 Apr 1;84(7):528-30. No abstract available.

PMID:
1545443
6.

Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo.

Waud WR, Gilbert KS, Harrison SD Jr, Griswold DP Jr.

Cancer Chemother Pharmacol. 1992;31(3):255-7.

PMID:
1361163
7.

Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.

Waud WR, Plowman J, Harrison SD Jr, Dykes DJ, Anderson WK, Griswold DP Jr.

Cancer Chemother Pharmacol. 1992;30(4):261-6.

PMID:
1322803
8.

Tumor models in drug development.

Griswold DP Jr, Harrison SD Jr.

Cancer Metastasis Rev. 1991 Oct;10(3):255-61. Review.

PMID:
1764768
9.

Practical spontaneous metastasis model for in vivo therapeutic studies using a human melanoma.

Shoemaker RH, Dykes DJ, Plowman J, Harrison SD Jr, Griswold DP Jr, Abbott BJ, Mayo JG, Fodstad O, Boyd MR.

Cancer Res. 1991 Jun 1;51(11):2837-41.

10.
11.

Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.

Waud WR, Harrison SD Jr, Gilbert KS, Laster WR Jr, Griswold DP Jr.

Cancer Chemother Pharmacol. 1991;27(6):456-63.

PMID:
1849465
12.

Evaluation of combinations of interferons and cytotoxic drugs in murine tumor models in vivo.

Harrison SD Jr, Stevens JJ, Waud WR, Dykes DJ, Schmid SM, Griswold DP Jr.

J Biol Response Mod. 1990 Aug;9(4):395-400.

PMID:
2118561
13.

Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice.

Waud WR, Leopold WR, Elliott WL, Dykes DJ, Laster WR Jr, Temple CG Jr, Harrison SD Jr, Griswold DP Jr.

Cancer Res. 1990 Jun 1;50(11):3239-44.

14.

Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.

Harrison SD Jr, Plowman J, Dykes DJ, Waud WR, Griswold DP Jr.

Cancer Chemother Pharmacol. 1990;25(6):425-9.

PMID:
2311170
15.

Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors.

Plowman J, Harrison SD, Dykes DJ Jr, Paull KD, Narayanan VL, Tobol HK, Martin J, Griswold DP Jr.

Cancer Res. 1989 Apr 15;49(8):1909-15.

16.

Antitumor activity of 2-chloroethyl (methylsulfonyl)methanesulfonate (clomesone, NSC 33847) against selected tumor systems in mice.

Dykes DJ, Waud WR, Harrison SD Jr, Laster WR Jr, Griswold DP Jr, Shealy YF, Montgomery JA.

Cancer Res. 1989 Mar 1;49(5):1182-6.

17.
18.

Predictive model for plasma concentration-versus-time profiles of investigational anticancer drugs in patients.

Davis LE, Alberts DS, Plezia PM, Roe DJ, Griswold DP.

J Natl Cancer Inst. 1988 Aug 3;80(11):815-9.

PMID:
3392741
19.

Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo.

Harrison SD Jr, Brockman RW, Trader MW, Laster WR Jr, Griswold DP Jr.

Invest New Drugs. 1987 Dec;5(4):345-51.

PMID:
3436739
20.

Experimental antitumor activity of the amsacrine analogue CI-921.

Leopold WR 3rd, Corbett TH, Griswold DP Jr, Plowman J, Baguley BC.

J Natl Cancer Inst. 1987 Aug;79(2):343-9.

PMID:
3474465
21.

Response of drug-sensitive and -resistant L1210 leukemias to high-dose chemotherapy.

Griswold DP Jr, Trader MW, Frei E 3rd, Peters WP, Wolpert MK, Laster WR Jr.

Cancer Res. 1987 May 1;47(9):2323-7.

22.

Preclinical antitumor activity and pharmacological properties of deoxyspergualin.

Plowman J, Harrison SD Jr, Trader MW, Griswold DP Jr, Chadwick M, McComish MF, Silveira DM, Zaharko D.

Cancer Res. 1987 Feb 1;47(3):685-9.

23.

Evaluation of trans-tetrachloro-1,2-diaminocyclohexane platinum (IV) in murine leukemia L1210 resistant and sensitive to cis-diamminedichloroplatinum (II).

Wilkoff LJ, Dulmadge EA, Trader MW, Harrison SD Jr, Griswold DP Jr.

Cancer Chemother Pharmacol. 1987;20(2):96-100.

PMID:
3664938
25.

Body burden of cancer in relationship to therapeutic outcome: consideration of preclinical evidence.

Griswold DP Jr.

Cancer Treat Rep. 1986 Jan;70(1):81-6. No abstract available.

PMID:
3943116
26.

Cell cycle effects of trimetrexate (CI-898).

Hook KE, Nelson JM, Roberts BJ, Griswold DP, Leopold WR.

Cancer Chemother Pharmacol. 1986;16(2):116-20.

PMID:
2936525
27.

Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology.

Schabel FM Jr, Griswold DP Jr, Corbett TH, Laster WR Jr.

Cancer. 1984 Sep 15;54(6 Suppl):1160-7. No abstract available.

PMID:
6467147
28.

Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr.

Cancer Res. 1984 Feb;44(2):717-26.

29.

Frank M. Schabel 1918-1983.

Skipper HE, Griswold DP.

Cancer Res. 1984 Feb;44(2):871-2. No abstract available.

30.

Review: scientific basis of adjuvant chemotherapy in breast cancer.

Griswold DP.

Recent Results Cancer Res. 1984;96:46-7. No abstract available.

PMID:
6528091
31.

The preclinical scientific basis for adjuvant chemotherapy in breast cancer.

Griswold DP Jr, Laster WR Jr, Trader MW, Dykes DJ.

Recent Results Cancer Res. 1984;96:1-7. No abstract available.

PMID:
6528086
32.

Therapeutic activity of mitoxantrone and ametantrone against murine tumors.

Schabel FM Jr, Corbett TH, Griswold DP Jr, Laster WR Jr, Trader MW.

Cancer Treat Rev. 1983 Dec;10 Suppl B:13-21. Review. No abstract available.

PMID:
6362874
33.

Establishment of cross-resistance profiles for new agents.

Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH.

Cancer Treat Rep. 1983 Oct;67(10):905-22. Review.

PMID:
6354439
34.

Concepts for the treatment of tumor metastasis.

Griswold DP Jr, Schabel FM Jr, Dykes DJ, Trader MW, Laster WR Jr.

Symp Fundam Cancer Res. 1983;36:389-96. Review. No abstract available.

PMID:
6382515
35.

Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology.

Schabel FM Jr, Griswold DP Jr, Corbett TH, Laster WR Jr.

Pharmacol Ther. 1983;20(2):283-305. Review. No abstract available.

PMID:
6351113
36.

Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents.

Corbett TH, Roberts BJ, Trader MW, Laster WR Jr, Griswold DP Jr, Schabel FM Jr.

Cancer Treat Rep. 1982 May;66(5):1187-200.

PMID:
7083221
37.

Toxicity and anticancer activity of a new triazine antifolate (NSC 127755).

Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP Jr, Schabel FM Jr.

Cancer Res. 1982 May;42(5):1707-15.

38.

Drug control of Ara-C-resistant tumor cells.

Schabel FM Jr, Skipper HE, Trader MW, Brockman RW, Laster WR Jr, Corbett TH, Griswold DP Jr.

Med Pediatr Oncol. 1982;10 Suppl 1:125-48. No abstract available.

PMID:
7162459
39.

Clonogenicity and growth of experimental tumors in relation to developing resistance and therapeutic failure.

Griswold DP, Corbett TH, Schabel FM Jr.

Cancer Treat Rep. 1981;65 Suppl 2:51-4. No abstract available.

PMID:
7346146
40.

Absence of delayed lethality in mice treated with aclacinomycin A.

Corbett TH, Griswold DP Jr, Roberts BJ, Schabel FM Jr.

Cancer Chemother Pharmacol. 1981;6(2):161-8.

PMID:
6946879
41.

The cell population kinetics and response to an S-phase specific agent of three transplantable colon tumor lines.

Simpson-Herren L, Corbett TH, Griswold DP.

Cell Tissue Kinet. 1980 Nov;13(6):613-24.

PMID:
7417978
42.

Concepts for controlling drug-resistant tumor cells.

Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr.

Eur J Cancer. 1980;Suppl 1:199-211. No abstract available.

PMID:
6947891
43.

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr.

Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1459-73.

PMID:
291480
44.

Design and evaluation of combination chemotherapy trials in experimental animal tumor systems.

Corbett TH, Griswold DP Jr, Wolpert MK, Venditti JM, Schabel FM Jr.

Cancer Treat Rep. 1979 May;63(5):799-801. No abstract available.

PMID:
455319
45.

Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy.

Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr.

Cancer Treat Rep. 1978 Oct;62(10):1471-88.

PMID:
709550
46.

Studies of the growth, population kinetics, and host lethality of CD8F mammary adenocarcinoma.

Simpson-Herren L, Griswold DP Jr, Corbett TH.

Cancer Treat Rep. 1978 Apr;62(4):519-28.

PMID:
657148
47.

Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas.

Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr.

Cancer. 1977 Nov;40(5 Suppl):2660-80. No abstract available.

PMID:
922705
48.

Growth support of small B16 melanoma implants with nitrosourea-sterilized fractions of the same tumor.

Dykes DJ, Griswold DP Jr, Schabel FM Jr.

Cancer Res. 1976 Jun;36(6):2031-4.

49.

Breast tumor modeling for prognosis and treatment.

Griswold DP Jr, Corbett TH.

Recent Results Cancer Res. 1976;(57):42-58. No abstract available.

PMID:
1013511
50.

A colon tumor model for anticancer agent evaluation.

Griswold DP, Corbett TH.

Cancer. 1975 Dec;36(6 Suppl):2441-4.

PMID:
1212662

Supplemental Content

Loading ...
Support Center